1. gerhart1
2. larryendo
3. obdi4439
4. learningtolearn2
5. captainfh
1.obdi4439 06/14/2018
Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47
2.learningtolearn2 03/22/2018
Trillium Therapeutics' TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
3.gerhart1 03/10/2018
Trillium Therapeutics Reports Annual 2017 Financial and Operating Results
4.gerhart1 04/19/2018
Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting
5.gerhart1 03/14/2018
Granted orphan drug designation by the FDA for its compound for the treatment of Cutaneous T-Cell Lymphoma
6.gerhart1 03/12/2018
H.C. Wainwright & Co. sets PT at $10
7.larryendo 03/20/2018
Has been granted an Orphan Drug Designation to TTI-621 for the treatment of cutaneous T-cell lymphoma
8.larryendo 06/05/2018
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW